Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial
T. Maher (London, United Kingdom), G. Jenkins (Nottingham, United Kingdom), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), I. Noth (Virginia, United States of America), M. Selman (Mexico City, Mexico), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), E. White (Michigan, United States of America)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Maher (London, United Kingdom), G. Jenkins (Nottingham, United Kingdom), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), I. Noth (Virginia, United States of America), M. Selman (Mexico City, Mexico), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), E. White (Michigan, United States of America). Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. 1922
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: